The first-in-human (FIH) study of Rova-T yielded an objective response rate (ORR) of 18%, which increased to 38% in DLL3-high patients with SCLC (patients whose tumors expressed DLL3 on ≥ 50% of cells by immunohistochemistry [IHC]) [31]. This evidence concerns the gene DLL3 and small cell lung carcinoma.